Skip to content
Open access · US-GOV via ClinicalTrials.gov Clinical trial

A Multicenter, Open-label, Dose Escalation Study Assessing the Safety and Treatment Effects of MS-553 in Diabetic Retinopathy Patients With Central Involved Macular Edema

Authors not listed

Shenzhen MingSight Relin Pharmaceuticals Co., Ltd. · 2020

Abstract

This is an open label dose-escalation study to evaluate the safety and treatment benefits of MS-553 in treatment-naive diabetic retinopathy patients with central involved macular edema. Fifteen subjects with diabetic macular edema will be enrolled into each of three dose cohorts and will receive oral administration of MS-553 for 8 weeks.

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source
ClinicalTrials.gov
Canonical
link ↗
Fetched
2026-11-15 MST

Cite this

APA
Anonymous. (2020). A Multicenter, Open-label, Dose Escalation Study Assessing the Safety and Treatment Effects of MS-553 in Diabetic Retinopathy Patients With Central Involved Macular Edema. <em>Shenzhen MingSight Relin Pharmaceuticals Co., Ltd.</em>. https://clinicaltrials.gov/study/NCT04187443
Vancouver
Anonymous. A Multicenter, Open-label, Dose Escalation Study Assessing the Safety and Treatment Effects of MS-553 in Diabetic Retinopathy Patients With Central Involved Macular Edema. Shenzhen MingSight Relin Pharmaceuticals Co., Ltd.. 2020.
BibTeX
@misc{anon2020AMulti, title = {A Multicenter, Open-label, Dose Escalation Study Assessing the Safety and Treatment Effects of MS-553 in Diabetic Retinopathy Patients With Central Involved Macular Edema}, author = {Anonymous}, journal = {Shenzhen MingSight Relin Pharmaceuticals Co., Ltd.}, year = {2020}, }

Research neighborhood

References, citing works, and semantically nearest findings. Click a node to open it.

Related findings